drugset / Trial / NCT04204889
Trial of Oxaloacetate in ALS
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and the maximal tolerated dose of Oxaloacetate (OAA) in patients with Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2020-03-17
- Primary completion
- 2023-08-02
- Completion
- 2023-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaloacetic Acid | Unknown | 500 mg | Oral |
| Subject | Oxaloacetic Acid | Unknown | 1000 mg | Oral |
| Subject | Oxaloacetic Acid | Unknown | 1500 mg | Oral |
| Subject | Oxaloacetic Acid | Unknown | 2000 mg | Oral |
| Subject | Oxaloacetic Acid | Unknown | 2500 mg | Oral |